Status:
COMPLETED
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Lead Sponsor:
Predictive Biosciences
Conditions:
Bladder Cancer Recurrence
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to detect recurrent bladder cancer using a combination of protein and DNA biomarkers in urine
Eligibility Criteria
Inclusion
- Intact bladder
- Scheduled for cystoscopy for transitional cell bladder cancer recurrence screening
- Urine donated prior to cystoscopy, Bladder biopsy, chemotherapy, intravesical therapy, radiation or TUR
- Must be willing to sign IRB approved informed consent
Exclusion
- History or current diagnosis of any cancer except transitional cell bladder cancer or basal cell cancer
- Known diagnosis of any autoimmune disease or HIV, HCV or HBV
- History or current TB or any other active infection
- Subject has gross hematuria
- Receiving chemotherapy, intravesical therapy or radiation within 30 days of enrollment
- Any surgery except urologic within past 30 days
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2010
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00903240
Start Date
May 1 2009
End Date
October 1 2010
Last Update
June 8 2011
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
BCG Oncology
Phoenix, Arizona, United States, 85032
2
Urology Associates
Engelwood, Colorado, United States, 80113
3
Atlantic Urological Associates
Daytona Beach, Florida, United States, 32114
4
Winter Park Urology
Orlando, Florida, United States, 32803